Medtronic (MDT)
NYSE:MDT
MDT Stock Chart & Stats
$87.17
$2.56(3.21%)
At close: 4:00 PM EST
$87.17
$2.56(3.21%)
Day’s Range― - ―
52-Week Range$79.55 - $106.33
Previous CloseN/A
Volume4.67M
Average Volume (3M)8.47M
Market Cap
$111.92B
Enterprise Value$138.08B
Total Cash (Recent Filing)$8.38B
Total Debt (Recent Filing)$28.07B
Price to Earnings (P/E)28.3
Beta0.49
Next Earnings
May 20, 2026EPS Estimate
1.67Next Dividend Ex-DateN/A
Dividend Yield2.76%
Share Statistics
EPS (TTM)1.36
Shares Outstanding1,283,885,000
10 Day Avg. Volume8,518,667
30 Day Avg. Volume8,472,942
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)2.25
Price to Sales (P/S)3.23
P/FCF Ratio20.87
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue3.89
Enterprise Value/Gross Profit6.28
Enterprise Value/Ebitda14.76
Forecast
1Y Price Target
$112.36Price Target Upside28.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)5.65
Revenue Forecast (FY)$36.16B
Bulls Say, Bears Say
Bulls Say
Cardiovascular Product LaunchesSuccessful execution of major cardiovascular launches, including renal denervation and newer valve iterations, could drive market share gains and provide significant upside to revenue.
Neurovascular Acquisition And Portfolio ExpansionAcquisition of a neurovascular access company expands the stroke treatment lineup and could accelerate sales by leveraging a larger global sales force and broader product offering.
Revenue Growth And Product-level DriversAnalyst highlights accelerating revenue growth supported by a detailed bottom-up model showing multiple product and business-level drivers that could add meaningful dollar growth across the company.
Bears Say
Core Surgery Segment WeaknessOngoing headwinds in stapling and bariatrics weaken the core surgery business, making that segment harder to forecast and limiting its contribution to overall revenue growth.
Diabetes Unit IPO DilutionCompletion of the diabetes unit IPO caused dilution that reduced earnings per share estimates and may weigh on near-term reported profitability.
Valve Durability And Reintervention RiskExtended follow-up showing increased late reinterventions linked to valve leakage raises concerns about long-term durability that could reduce clinician preference and erode market share in some anatomies.
Medtronic News
MDT FAQ
What was Medtronic’s price range in the past 12 months?
Medtronic lowest stock price was $79.55 and its highest was $106.33 in the past 12 months.
What is Medtronic’s market cap?
Medtronic’s market cap is $111.92B.
When is Medtronic’s upcoming earnings report date?
Medtronic’s upcoming earnings report date is May 20, 2026 which is in 56 days.
How were Medtronic’s earnings last quarter?
Medtronic released its earnings results on Feb 17, 2026. The company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.337 by $0.023.
Is Medtronic overvalued?
According to Wall Street analysts Medtronic’s price is currently Undervalued.
Does Medtronic pay dividends?
Medtronic pays a Quarterly dividend of $0.71 which represents an annual dividend yield of 2.76%. See more information on Medtronic dividends here
What is Medtronic’s EPS estimate?
Medtronic’s EPS estimate is 1.67.
How many shares outstanding does Medtronic have?
Medtronic has 1,283,885,000 shares outstanding.
What happened to Medtronic’s price movement after its last earnings report?
Medtronic reported an EPS of $1.36 in its last earnings report, beating expectations of $1.337. Following the earnings report the stock price went down -3.096%.
Which hedge fund is a major shareholder of Medtronic?
Currently, no hedge funds are holding shares in MDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medtronic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$112.36 (28.90% Upside)
$112.36 (28.90% Upside)
Blogger Sentiment
Bullish
MDT Sentiment 89%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.45%
12-Months-Change
Fundamentals
Return on Equity
9.54%
Trailing 12-Months
Asset Growth
1.68%
Trailing 12-Months
Company Description
Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
MDT Company Deck
MDT Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents materially more positive operational and financial developments than negatives: strong top-line beat, multiple high-growth product franchises showing early traction (CAS/PFA, CRM products, MiniMed), regulatory approvals and early commercialization wins (Hugo, Stealth AXiS), and improved margins and EPS above guidance. Headwinds include mix-related gross margin pressure from early-stage launches, tariff and tax impacts, some softer neuroscience and surgical subsegments, and temporary dilution around the MiniMed separation and M&A. Management provided quantified guidance on tariff impacts and reiterated fiscal guidance while outlining a clear path for margin recovery and growth investments.View all MDT earnings summariesMDT Net sales Breakdown
36.56% Cardiovascular
29.06% Neuroscience
26.01% Medical Surgical
7.69% Diabetes
0.68% Other operating segment
MDT Stock 12 Month Forecast
Average Price Target
$112.36
▲(28.90% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
24.84% Mutual Funds
17.54% Other Institutional Investors
34.78% Public Companies and Individual Investors